SCHEMBL5724968

SCHEMBL5724968

CS(=O)(=O)NCCOc1cc(Cl)cc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.51
▸ HTT P42858 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ MAPT P10636 2/20 0.47
▸ PKM P14618 2/20 0.44
▸ ROCK2 O75116 2/20 0.43
▸ MAP4K4 O95819 2/20 0.43
▸ PIM1 P11309 2/20 0.43
▸ PRKACA P17612 2/20 0.43
▸ CDK2 P24941 2/20 0.43
▸ GSK3B P49841 2/20 0.43
▸ HIPK2 Q9H2X6 2/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ CDK1 P06493 1/20 0.43
▸ ROS1 P08922 1/20 0.43
▸ RPS6KB1 P23443 1/20 0.43
▸ AKT1 P31749 1/20 0.43
▸ CLK2 P49760 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5725084 0.84 KMT2A (0.58) ALDH1A1HTTMEN1KMT2APKM
SCHEMBL27002695 0.78 ALDH1A1 (0.50) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL15262441 0.77 ALDH1A1 (0.50) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL10922023 0.76 MAPT (0.55) ALDH1A1KMT2AMAPTKDM4ELMNA
SCHEMBL9142888 0.75 MEN1 (0.79) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL10336962 0.74 ALDH1A1 (0.69) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL10191940 0.74 ALDH1A1 (0.65) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL23640331 0.73 ALDH1A1 (0.57) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL15904066 0.72 ALDH1A1 (0.59) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL7103943 0.72 MAPT (0.50) KMT2AMAPTF2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 — — EP disclosed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 — — US disclosed
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC 2004-09-09 — — US disclosed
US-6649657-B2 Administering amide to treat osteoporosis PFIZER INC. 2003-11-18 — — US disclosed
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLEY Q (US) 2003-06-05 — — US disclosed
US-6492412-B2 ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. PFIZER, INC. 2002-12-10 — — US disclosed
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists CAMERON KIMBERLY O (US) 2002-02-07 — — US disclosed
US-6344485-B1 Method for treating glaucoma PFIZER INC. 2002-02-05 — — US disclosed
US-6288120-B1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. 2001-09-11 — — US disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 — — EP disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 — — EP disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176461-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885HTT 4781/4885MEN1 3257/4885
US-20020016368-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885HTT 4781/4885MEN1 3257/4885
US-20030105092-A1 Prevention of loss and restoration of bone mass by certain prostaglandin agonists HPGDS, PTGIR, PTGER1 ALDH1A1 2216/4885HTT 4781/4885MEN1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback